<DOC>
	<DOCNO>NCT00463437</DOCNO>
	<brief_summary>The purpose study assess safety term fever ( rectal temperature ) high 39 degree Celcius ( Â°C ) immunogenicity term antibody response follow booster vaccination pneumococcal vaccine GSK1024850A 11 18 month age child previously prim vaccine include pneumococcal conjugate vaccine co-administered diphtheria , tetanus , acellular pertussis ( DTPa ) -combined meningococcal serogroup C ( MenC ) combine meningococcal serogroup C Haemophilus influenzae type b ( Hib-MenC ) vaccine . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00334334 ) .</brief_summary>
	<brief_title>Pneumococcal Vaccine Booster Study Healthy Children 11-18 Months Old Previously Primed With Same Vaccines</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 1118 month age time booster vaccination . A male female previously participate study 107005 receive three dos pneumococcal conjugate vaccine . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Concurrently participate another clinical study , time study period ( active phase extend safety followup ) , subject expose investigational noninvestigational product . Use investigational nonregistered product ( drug vaccine ) study vaccine within one month precede booster dose study vaccine , plan use entire study period Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior booster dose study vaccine . Planned administration/administration vaccine foreseen study protocol , period start one month booster dose study vaccine followup visit ( one month booster dose study vaccine ) . Administration pneumococcal , diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b , MenC and/or HibMenC vaccine study vaccine study 107005 . History , intercurrent , diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b , meningococcal serogroup C disease . History allergic disease reaction likely exacerbate component vaccine . History seizure ( criterion apply subject single , uncomplicated febrile convulsion past ) progressive neurological disease . Acute disease time enrolment . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins and/or blood product within three month precede booster dose study vaccine plan administration active phase study ( start administration booster dose study vaccine followup visit one month ) .</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fever .</keyword>
	<keyword>Meningococcal disease .</keyword>
	<keyword>Pneumococcal disease .</keyword>
	<keyword>Meningococcal vaccine .</keyword>
	<keyword>Pneumococcal vaccine .</keyword>
	<keyword>Immunogenicity .</keyword>
	<keyword>Booster vaccination .</keyword>
	<keyword>Safety .</keyword>
</DOC>